Dang NH - Search Results

1

CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).

Sato K, Dang NH. Sato K, et al. Among authors: dang nh. Int J Oncol. 2003 Mar;22(3):481-97. Int J Oncol. 2003. PMID: 12579300 Review.

2

CD26 in T-cell lymphomas: a potential clinical role?

Verstovsek S, Cabanillas F, Dang NH. Verstovsek S, et al. Among authors: dang nh. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):17-23. Oncology (Williston Park). 2000. PMID: 10887640 Free article. Review.

3

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood.

Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Jones D, et al. Among authors: dang nh. Am J Clin Pathol. 2001 Jun;115(6):885-92. doi: 10.1309/U1Y6-J4AG-5M4M-7AYV. Am J Clin Pathol. 2001. PMID: 11392886

4

In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.

Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH. Ho L, et al. Among authors: dang nh. Clin Cancer Res. 2001 Jul;7(7):2031-40. Clin Cancer Res. 2001. PMID: 11448921

5

Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint.

Aytac U, Claret FX, Ho L, Sato K, Ohnuma K, Mills GB, Cabanillas F, Morimoto C, Dang NH. Aytac U, et al. Among authors: dang nh. Cancer Res. 2001 Oct 1;61(19):7204-10. Cancer Res. 2001. PMID: 11585756

6

CD26: an expanding role in immune regulation and cancer.

Dang NH, Morimoto C. Dang NH, et al. Histol Histopathol. 2002 Oct;17(4):1213-26. doi: 10.14670/HH-17.1213. Histol Histopathol. 2002. PMID: 12371149 Review.

7

Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors.

Aytac U, Sato K, Yamochi T, Yamochi T, Ohnuma K, Mills GB, Morimoto C, Dang NH. Aytac U, et al. Among authors: dang nh. Br J Cancer. 2003 Feb 10;88(3):455-62. doi: 10.1038/sj.bjc.6600791. Br J Cancer. 2003. PMID: 12569391 Free PMC article.

8

T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition.

Dang NH, Aytac U, Sato K, O'Brien S, Melenhorst J, Morimoto C, Barrett AJ, Molldrem JJ. Dang NH, et al. Br J Haematol. 2003 Jun;121(6):857-65. doi: 10.1046/j.1365-2141.2003.04365.x. Br J Haematol. 2003. PMID: 12786796 Free article.

9

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.

Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Dang NH, et al. Oncol Rep. 2003 Sep-Oct;10(5):1513-8. Oncol Rep. 2003. PMID: 12883733 Clinical Trial.

10

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors.

Sato K, Aytac U, Yamochi T, Yamochi T, Ohnuma K, McKee KS, Morimoto C, Dang NH. Sato K, et al. Among authors: dang nh. Br J Cancer. 2003 Oct 6;89(7):1366-74. doi: 10.1038/sj.bjc.6601253. Br J Cancer. 2003. PMID: 14520473 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page